You may be able to participate in the ASPEN clinical study if you:
Are between the ages
of 18–85 years of age.
Have non-cystic fibrosis bronchiectasis (NCFBE).
Your participation in this study will help increase the knowledge and understanding of NCFBE to potentially benefit the broader NCFBE patient community.
By enrolling in this phase 3 trial, you may be given a study drug being evaluated for:
The purpose of this study is to assess a study drug as a potential treatment of non-cystic fibrosis bronchiectasis (NCFBE).
Click here to fill out an application.
The study will be conducted in various regions across the world.
The drug will be taken orally once per day before breakfast on an empty stomach.
This study drug is being evaluated to see if it decreases lung inflammation that leads to bronchiectasis.
Yes, there have been other clinical studies. This study drug was previously tested in a Phase 2 trial.
To evaluate the effects and dosage of the study drug on adult NCFBE patients.
Health insurance is not required to participate in this study.
The study will last up to 62 weeks.
There will be no charge for your participation in this study.
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience. Headquartered in the United States, Insmed is a rapidly growing company with more than 500 employees around the world.
A clinical study for people with non-cystic fibrosis bronchiectasis (NCFBE).
